Genertec Universal Medical Group Company Limited

SEHK:2666 Stock Report

Market Cap: HK$8.9b

Genertec Universal Medical Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Wang Wenbing

Chief executive officer

CN¥4.5m

Total compensation

CEO salary percentage32.2%
CEO tenure7.9yrs
CEO ownershipn/a
Management average tenure1.8yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Earnings Working Against Genertec Universal Medical Group Company Limited's (HKG:2666) Share Price

Oct 09
Earnings Working Against Genertec Universal Medical Group Company Limited's (HKG:2666) Share Price

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

May 22
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group Company Limited's (HKG:2666) Price Is Right But Growth Is Lacking

May 10
Genertec Universal Medical Group Company Limited's (HKG:2666) Price Is Right But Growth Is Lacking

Why Investors Shouldn't Be Surprised By Genertec Universal Medical Group Company Limited's (HKG:2666) Low P/E

Feb 05
Why Investors Shouldn't Be Surprised By Genertec Universal Medical Group Company Limited's (HKG:2666) Low P/E

Genertec Universal Medical Group (HKG:2666) Is Reducing Its Dividend To CN¥0.34

Jun 08
Genertec Universal Medical Group (HKG:2666) Is Reducing Its Dividend To CN¥0.34

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 08
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Should You Be Adding Genertec Universal Medical Group (HKG:2666) To Your Watchlist Today?

Aug 20
Should You Be Adding Genertec Universal Medical Group (HKG:2666) To Your Watchlist Today?

Here's Why We Think Genertec Universal Medical Group (HKG:2666) Is Well Worth Watching

Apr 19
Here's Why We Think Genertec Universal Medical Group (HKG:2666) Is Well Worth Watching

Shareholders Of Genertec Universal Medical Group (HKG:2666) Must Be Happy With Their 34% Return

Mar 10
Shareholders Of Genertec Universal Medical Group (HKG:2666) Must Be Happy With Their 34% Return

Is Genertec Universal Medical Group Company Limited (HKG:2666) Trading At A 48% Discount?

Feb 19
Is Genertec Universal Medical Group Company Limited (HKG:2666) Trading At A 48% Discount?

Did Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Buy Up More Shares?

Feb 01
Did Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Buy Up More Shares?

The Case For Genertec Universal Medical Group Company Limited (HKG:2666): Could It Be A Nice Addition To Your Dividend Portfolio?

Jan 11
The Case For Genertec Universal Medical Group Company Limited (HKG:2666): Could It Be A Nice Addition To Your Dividend Portfolio?

What Kind Of Investors Own Most Of Genertec Universal Medical Group Company Limited (HKG:2666)?

Dec 21
What Kind Of Investors Own Most Of Genertec Universal Medical Group Company Limited (HKG:2666)?

Reflecting on Genertec Universal Medical Group's (HKG:2666) Share Price Returns Over The Last Three Years

Nov 30
Reflecting on Genertec Universal Medical Group's (HKG:2666) Share Price Returns Over The Last Three Years

CEO Compensation Analysis

How has Wang Wenbing's remuneration changed compared to Genertec Universal Medical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥4mCN¥1m

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥2b

Dec 31 2022CN¥4mCN¥1m

CN¥2b

Sep 30 2022n/an/a

CN¥2b

Jun 30 2022n/an/a

CN¥2b

Mar 31 2022n/an/a

CN¥2b

Dec 31 2021CN¥2mCN¥731k

CN¥2b

Compensation vs Market: Wang's total compensation ($USD612.28K) is about average for companies of similar size in the Hong Kong market ($USD471.00K).

Compensation vs Earnings: Wang's compensation has been consistent with company performance over the past year.

CEO

Wang Wenbing (50 yo)

7.9yrs

Tenure

CN¥4,489,000

Compensation

Mr. Wang Wenbing is General Manager of China Universal Leasing Co., Ltd since October 14, 2021. He has been Deputy General Manager of Genertec Universal Medical Group Company Limited (formerly known as Uni...

Leadership Team

NamePositionTenureCompensationOwnership
Wang Wenbing
CEO & Executive Director7.9yrsCN¥4.49mno data
Lin Wang
Executive Director1.5yrsCN¥965.00kno data
Shisu Chen
Executive Chairmanless than a yearno datano data
Shinan Wang
Chief Accounting Officer & General Counsel1.8yrsno datano data
Feng Qingming
Chief Medical Officerno datano datano data
Wai Kam Ng
Company Secretary5.1yrsno datano data

1.8yrs

Average Tenure

50yo

Average Age

Experienced Management: 2666's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Wang Wenbing
CEO & Executive Director3.3yrsCN¥4.49mno data
Lin Wang
Executive Director1.5yrsCN¥965.00kno data
Shisu Chen
Executive Chairmanless than a yearno datano data
Yinquan Li
Independent Non-Executive Director9.6yrsCN¥363.00kno data
Zhiming Xu
Independent Non-executive Director2.6yrsCN¥363.00kno data
Kai Kong Chan
Non-Executive Vice-Chairman2.6yrsno data0.0016%
HK$ 141.1k
Siu Lui Chow
Independent Non-Executive Director9.6yrsCN¥363.00kno data
Ming Xu
Non-Executive Director2.6yrsno datano data
Chaoyin Tong
Non-Executive Director3.7yrsno datano data
Hiu Fung Chan
Independent Non-executive Director2.6yrsCN¥363.00kno data
Ziyang Zhu
Non-Executive Director3.5yrsno datano data

2.6yrs

Average Tenure

55yo

Average Age

Experienced Board: 2666's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 19:40
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genertec Universal Medical Group Company Limited is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yolanda YinCGS International
Yolanda YinChina Galaxy International Securities (Hong Kong)
Fangqi DaiChina Merchants Securities (HK) Co., Ltd